| Literature DB >> 16387387 |
Janakiraman Subramanian1, Giancarlo Pillot, Vamsidhar Narra, Ramaswamy Govindan.
Abstract
A 65-year-old male with 40-pack year smoking history presented with exertional dyspnea and was subsequently diagnosed with bronchiolo-alveolar carcinoma (BAC). He did not respond to first line therapy with geftinib, but he achieved disease stabilization with gemcitabine and carboplatin for 4 months before developing symptomatic worsening requiring oxygen supplementation. He responded dramatically to bortezomib with rapid symptom improvement. The follow-up computerized tomography revealed partial response that was maintained for 11 months. Based on observations like this and those seen in phase I studies with bortezomib, this agent is being studied now in patients with bronchio-alevolar cancer.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16387387 DOI： 10.1016/j.lungcan.2005.10.007
Source DB: PubMed Journal: Lung Cancer ISSN： 0169-5002 Impact factor: 5.705